The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer
Official Title: A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Study ID: NCT01836679
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Chidamide combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Detailed Description: The study is to evaluate efficacy which includes the progression free survival (PFS), PFS at 6 months, objective response rate, duration of response rate, overall survival and time to progression, and safety which include adverse events, vital signs, laboratory tests, of the treatment of chidamide plus paclitaxel and carboplatin in patients with advanced non small cell lung cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
The first Hospital of China Medical University, Shenyang, Liaoning, China
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
The Second People's Hospital of Sichuan, Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Name: Yuankai Shi
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR